Compare NDAQ & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NDAQ | BDX |
|---|---|---|
| Founded | 1971 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1B | 43.0B |
| IPO Year | 2001 | 1998 |
| Metric | NDAQ | BDX |
|---|---|---|
| Price | $96.68 | $182.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $105.62 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 3.0M | 1.7M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | 1.36% | ★ 2.89% |
| EPS Growth | ★ 60.10 | N/A |
| EPS | ★ 1.80 | 1.59 |
| Revenue | $4,277,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $10.52 | N/A |
| Revenue Next Year | $8.17 | $3.02 |
| P/E Ratio | ★ $53.90 | $115.35 |
| Revenue Growth | 7.87 | ★ 8.24 |
| 52 Week Low | $76.55 | $140.11 |
| 52 Week High | $101.79 | $213.08 |
| Indicator | NDAQ | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 64.88 | 73.58 |
| Support Level | $96.47 | $163.44 |
| Resistance Level | $101.50 | $187.35 |
| Average True Range (ATR) | 1.75 | 4.00 |
| MACD | 0.04 | 1.04 |
| Stochastic Oscillator | 83.40 | 89.79 |
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.